November 30, 2016Open Access

Targeted deep sequencing in primary myelofibrosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Key Points More than 80% of patients with PMF harbor DNA variants/mutations other than JAK2/CALR/MPL. Some of these variants/mutations adversely affect overall or leukemia-free survival independent of conventional risk stratification.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Tefferi et al. (Wed,) studied this question.

synapsesocial.com/papers/6a1023298090e499da60aebf https://doi.org/https://doi.org/10.1182/bloodadvances.2016000208

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients2014 · 308 citations
2Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis2014 · 728 citations
3New mutations and pathogenesis of myeloproliferative neoplasms2011 · 390 citations
4The<i>JAK2</i><sup>V617F</sup>tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates2005 · 206 citations
5The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,417 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo